» Articles » PMID: 11472746

The Methionine Synthase Reductase (MTRR) A66G Polymorphism is a Novel Genetic Determinant of Plasma Homocysteine Concentrations

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2001 Jul 27
PMID 11472746
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Epidemiological evidence has revealed that an elevated plasma homocysteine level (hyperhomocysteinemia) confers an increased risk of cardiovascular disease and neural tube defects. Hyperhomocysteinemia is caused by both nutritional (e.g. folate, vitamins B(6) and B(12)) and genetic factors, including functional polymorphisms of key enzymes involved in homocysteine metabolism. One such enzyme, methionine synthase reductase (MTRR), maintains adequate levels of methylcob(III)alamin, the activated cofactor for methionine synthase, which catalyzes the remethylation of homocysteine to methionine. A common MTRR polymorphism, i.e. a 66 A-->G substitution specifying an isoleucine to methionine substitution (I22M), was recently identified. To assess the influence of this polymorphism on total plasma homocysteine (tHcy), we undertook a genotype/phenotype analysis in a study population of 601 Northern-Irish men, aged 30--49, for which biochemical and genetic data relevant to folate/homocysteine metabolism had already been acquired. The 66AA genotype has a frequency of 29% in this population. We established that there was a significant influence of MTRR genotype on tHcy ranking (P=0.004) and that the 66AA genotype contributes to a moderate increase in tHcy levels across the distribution [OR 1.59 (95% CI: 1.10--2.25) for the 66AA genotype to be in the upper half of the tHcy distribution, P=0.03]. The homocysteine-elevating effect of the 66AA genotype is independent of serum folate, vitamin B(12) and vitamin B(6) levels. Based on published estimates of the enhanced cardiovascular disease risk conferred by defined increments of plasma tHcy, we estimate that 66AA homozygotes have, on average, an approximately 4% increase in cardiovascular disease risk compared to 66GG homozygotes. This study provides the first evidence that the MTRR A66G polymorphism significantly influences the circulating tHcy concentration.

Citing Articles

Association Between Folate Metabolism Risk, Collateral Circulation, and Hemorrhagic Risk in Moyamoya Disease.

Li J, He Q, Liu C, Zeng C, Zheng Z, Zhang B Transl Stroke Res. 2025; .

PMID: 39775251 DOI: 10.1007/s12975-024-01324-y.


Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) gene polymorphisms and five related serum molecular levels in 2587 patients: Associated differentially with adverse pregnancy.

Feng Z, Gao Y, Zhang M, Wang Y, Liu X, Zhang B Mol Biol Rep. 2024; 51(1):1014.

PMID: 39325209 DOI: 10.1007/s11033-024-09948-x.


Effect of Methylfolate, Pyridoxal-5'-Phosphate, and Methylcobalamin (Soloways) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with Methylenetetrahydrofolate Reductase, Methionine Synthase, and Methionine....

Pokushalov E, Ponomarenko A, Bayramova S, Garcia C, Pak I, Shrainer E Nutrients. 2024; 16(11).

PMID: 38892484 PMC: 11173557. DOI: 10.3390/nu16111550.


The Importance of Nutrigenetics and Microbiota in Personalized Medicine: From Phenotype to Genotype.

Meral G, Aslan E, Tunaligil V, Burkay N, Alper Acar E, Alp M Cureus. 2024; 16(5):e61256.

PMID: 38807972 PMC: 11132663. DOI: 10.7759/cureus.61256.


Epigenetic Genome Modifications during Pregnancy: The Impact of Essential Nutritional Supplements on DNA Methylation.

Socha M, Flis W, Wartega M Nutrients. 2024; 16(5).

PMID: 38474806 PMC: 10934520. DOI: 10.3390/nu16050678.